Effect of In-Hospital Initiation of Lipid-Lowering Therapy on Six-Month Outcomes in Patients With Acute Ischemic Stroke or Transient Ischemic Attack

American Journal of Cardiology

Volumn 105, Issue 10, 2010, Pages 1490-1494

  Yeh, Poh Shiow ^a   Lin, Huey Juan ^a   Bai, Chyi Huey ^b   Hsieh, Fang I ^b   Ke, Der Shin ^a   Li, Yi Heng ^c  

^a CHI MEI MEDICAL CENTER   (Taiwan)

^b Chi Chin Huang Taiwan Stroke Registry   (Taiwan)

^c NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; COLESTYRAMINE; EZETIMIBE; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NICOTINIC ACID;

ADULT; AGED; ARTICLE; BRAIN ISCHEMIA; CONTROLLED STUDY; DEATH; DRUG UTILIZATION; FEMALE; HOSPITAL CARE; HOSPITAL DISCHARGE; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRESCRIPTION; PRIORITY JOURNAL; RECURRENT DISEASE; TRANSIENT ISCHEMIC ATTACK;

AGED; AGED, 80 AND OVER; BRAIN ISCHEMIA; CONFIDENCE INTERVALS; CONTINUITY OF PATIENT CARE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HOSPITALIZATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; ISCHEMIC ATTACK, TRANSIENT; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATIENT DISCHARGE; PROBABILITY; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; REGISTRIES; RISK ASSESSMENT; STROKE; SURVIVAL RATE; TAIWAN; TIME FACTORS; TREATMENT OUTCOME;

EID: 77951667410     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2009.07.065     Document Type: Article

References (17)

1. Dennis M.S., Burn J.P., Sandercock P.A., Bamford J.M., Wade D.T., and Warlow C.P. Long-term survival after first-ever stroke: the Oxfordshire Community Stroke Project. Stroke 24 (1993) 796-800
2. Burn J.P., Dennis M.S., Bamford J.M., Sandercock P.A., Wade D.T., and Warlow C.P. Long-term risk of recurrent stroke after a first-ever stroke. Stroke 25 (1994) 333-337
3. Petty G.W., Brown Jr. R.D., Whisnant J.P., Sicks J.D., O'Fallon W.M., and Wiebers D.O. Survival and recurrence after first cerebral infarction: a population-based study in Rochester, Minnesota, 1975 through 1989. Neurology 50 (1998) 208-216
4. Lee L.J., Kidwell C.S., Alger J., Starkman S., and Saver J.L. Impact on stroke subtype diagnosis of early diffusion-weighted magnetic resonance imaging and magnetic resonance angiography. Stroke 31 (2000) 1081-1089
5. Rubin D.B. Estimating causal effects from large datasets using propensity scores. Ann Intern Med 127 (1997) 757-763
6. Laufs U., and Liao J.K. Rapid effects of statins: from prophylaxis to therapy for ischemic stroke. Arterioscler Thromb Vasc Biol 23 (2003) 156-157
7. Jonsson N., and Asplund K. Does pretreatment with statins improve clinical outcome after stroke?. A pilot case-referent study. Stroke 32 (2001) 1112-1115
8. Elkind M.S., Flint A.C., Sciacca R.R., and Sacco R.L. Lipid-lowering agent use at ischemic stroke onset is associated with decreased mortality. Neurology 65 (2005) 253-258
9. Moonis M., Kane K., Schwiderski U., Sandage B.W., and Fisher M. HMG-CoA reductase inhibitors improve acute ischemic stroke outcome. Stroke 36 (2005) 1298-1300
10. Prinz V., Laufs U., Gertz K., Kronenberg G., Balkaya M., Leithner C., Lindauer U., and Endres M. Intravenous rosuvastatin for acute stroke treatment: an animal study. Stroke 39 (2008) 433-438
11. Montaner J., Chacón P., Krupinski J., Rubio F., Millán M., Molina C.A., Hereu P., Quintana M., and Alvarez-Sabín J. Simvastatin in the acute phase of ischemic stroke: a safety and efficacy pilot trial. Eur J Neurol 15 (2008) 82-90
12. Stroke Council, American Heart Association, American Stroke Association. Statins after ischemic stroke and transient ischemic attack: an advisory statement from the Stroke Council American Heart Association and American Stroke Association. Stroke 35 (2004) 1023
13. Ovbiagele B., Saver J.L., Fredieu A., Suzuki S., Selco S., Rajajee V., McNair N., Razinia T., and Kidwell C.S. In-hospital initiation of secondary stroke prevention therapies yields high rates of adherence at follow-up. Stroke 35 (2004) 2879-2883
14. Lalouschek W., Lang W., Greisenegger S., Müllner M., and Vienna Stroke Study Group. Determination of lipid profiles and use of statins in patients with ischemic stroke or transient ischemic attack. Stroke 34 (2003) 105-110
15. Mullard A.J., Reeves M.J., Jacobs B.S., Kothari R.U., Birbeck G.L., Maddox K., Stoeckle-Roberts S., Wehner S., Paul C., and National Acute Stroke Registry Michigan Prototype Investigators. Lipid testing and lipid-lowering therapy in hospitalized ischemic stroke and transient ischemic attack patients: results from a statewide stroke registry. Stroke 37 (2006) 44-49
16. Chen T.J., Lin S.J., Chen L.K., Hwang S.J., and Chou L.F. Prevalence of antilipemic drug use in Taiwan: analysis of a sampling cohort within the national health insurance. J Chin Med Assoc 66 (2003) 39-45
17. Chiang C.W., Chiu H.F., Chen C.Y., Wu H.L., and Yang C.Y. Trends in the use of lipid-lowering drugs by outpatients with diabetes in Taiwan, 1997-2003. Pharmacoepidemiol Drug Saf 17 (2008) 62-69